Efficacy and tolerance of ivermectin in human onchocerciasis.
Initial clinical studies in 32 Senegalese subjects have demonstrated the efficacy of ivermectin in Onchocerca volvulus infection (river blindness). Although O. volvulus microfilariae in skin snips were not reduced in number after single oral doses of 5 micrograms or 10 micrograms/kg body-weight, they were greatly reduced in all subjects after single oral doses of 30 micrograms or 50 micrograms/kg and were eliminated completely in 6 of th 8 subjects who received the 50 micrograms/kg dose. All subjects tolerated the drug well. Transient pruritus which did not require treatment was observed on the day the dose was given in 2 of the 8 subjects after the 30 micrograms/kg dose and in 4 of the 8 who received the 50 micrograms/kg dose. Ivermectin produced no abnormal laboratory results.
D000328:Adult; D000871:Anthelmintics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D007559:Ivermectin; D007783:Lactones / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D009855:Onchocerciasis / Q000188:drug therapy*; D011897:Random Allocation
D000871:Anthelmintics; D007783:Lactones; D007559:Ivermectin